Provectus Biopharmaceuticals Inc
OTC:PVCT
Provectus Biopharmaceuticals Inc
Research & Development
Provectus Biopharmaceuticals Inc
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Provectus Biopharmaceuticals Inc
OTC:PVCT
|
Research & Development
-$2.2m
|
CAGR 3-Years
8%
|
CAGR 5-Years
4%
|
CAGR 10-Years
11%
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Research & Development
-$14.7B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
-5%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Research & Development
-$9.5B
|
CAGR 3-Years
0%
|
CAGR 5-Years
0%
|
CAGR 10-Years
-5%
|
|
|
Pfizer Inc
NYSE:PFE
|
Research & Development
-$10.4B
|
CAGR 3-Years
3%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
-3%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Research & Development
-$15.6B
|
CAGR 3-Years
-10%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
-9%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Research & Development
-$13.3B
|
CAGR 3-Years
-23%
|
CAGR 5-Years
-17%
|
CAGR 10-Years
-11%
|
|
Provectus Biopharmaceuticals Inc
Glance View
Provectus Biopharmaceuticals, Inc. is a development stage biopharmaceutical company. The company is headquartered in Knoxville, Tennessee and currently employs 4 full-time employees. The company went IPO on 2000-04-07. The firm is focused on developing immunotherapy medicines for different diseases, based on a family of small molecules called halogenated xanthenes (HXs). Its lead HX molecule, rose bengal sodium (RBS). Its product pipeline includes PV-10 and PH-10. Its PV-10 is an investigational cancer immunotherapy administered by intralesional (IL) injection and an injectable formulation of cGMP (current Good Manufacturing Practice) RBS, is undergoing clinical study for adult solid tumor cancers, such as melanoma and gastrointestinal (GI) tumors. PH-10 is an investigational immuno-dermatology agent administered as a topical gel and formulation of cGMP RBS, is undergoing monotherapy clinical study and preclinical study of combination therapy with approved drugs for inflammatory dermatoses. Its ongoing pre-clinical studies in other areas include hematology, virology, microbiology, ophthalmology, and animal health.
See Also
What is Provectus Biopharmaceuticals Inc's Research & Development?
Research & Development
-2.2m
USD
Based on the financial report for Jun 30, 2025, Provectus Biopharmaceuticals Inc's Research & Development amounts to -2.2m USD.
What is Provectus Biopharmaceuticals Inc's Research & Development growth rate?
Research & Development CAGR 10Y
11%
Over the last year, the Research & Development growth was -24%. The average annual Research & Development growth rates for Provectus Biopharmaceuticals Inc have been 8% over the past three years , 4% over the past five years , and 11% over the past ten years .
